Anjana Pillai to Hepatitis C, Chronic
This is a "connection" page, showing publications Anjana Pillai has written about Hepatitis C, Chronic.
Connection Strength
2.500
-
Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin. Aliment Pharmacol Ther. 2017 06; 45(11):1427-1432.
Score: 0.542
-
Caution: Reactivation of Hepatitis B during Hepatitis C Treatment with Direct-Acting Antiviral Therapy. Am J Gastroenterol. 2016 Dec; 111(12):1854-1856.
Score: 0.530
-
Simeprevir and Sofosbuvir (SMV-SOF) for 12 Weeks for the Treatment of Chronic Hepatitis C Genotype 1 Infection: A Real World (Transplant) Hepatology Practice Experience. Am J Gastroenterol. 2016 Feb; 111(2):250-60.
Score: 0.500
-
Prevention, Diagnosis, and Treatment of Hepatocellular Carcinoma. JAMA. 2024 09 24; 332(12):1013-1014.
Score: 0.228
-
Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma. Cancer. 2022 10 01; 128(19):3470-3478.
Score: 0.195
-
Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020 04; 18(4):974-983.
Score: 0.159
-
Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study. Gastroenterology. 2019 05; 156(6):1683-1692.e1.
Score: 0.153
-
Hepatitis B Virus Reactivation During Successful Treatment of Hepatitis C Virus With Sofosbuvir and Simeprevir. Clin Infect Dis. 2015 Oct 15; 61(8):1304-6.
Score: 0.120
-
Clinical significance of metabolic syndrome in the setting of chronic hepatitis C virus infection. Clin Gastroenterol Hepatol. 2008 May; 6(5):584-9.
Score: 0.073